Table 2.
Intervention related changes in declarative memory performance of MCI patients dependent on group and time.
| Resveratrol (n = 18) | Placebo (n = 22) | |||||||
|---|---|---|---|---|---|---|---|---|
| BL | FU | p-value | BL | FU | p-value | Unadjusted p-value (group × time)c | Adjusted p-value (group × time)d | |
| Learning ability | 44.9±9.5 | 43.0±10.7 | 0.314a | 44.2±8.1 | 41.9±12.8 | 0.495b | 0.878 | 0.840 |
| Delayed recall | 7.6±3.9 | 6.7±3.9 | 0.173a | 7.2±2.7 | 7.6±3.7 | 0.536a | 0.157 | 0.126 |
| Retention | −3.4±2.1 | −3.8±2.6 | 0.444a | −3.8±2.2 | −3.3±2.2 | 0.505a | 0.325 | 0.249 |
| Recognition | 9.8±5.9 | 8.4±6.2 | 0.122b | 9.3±4.2 | 7.7±6.0 | 0.152b | 0.882 | 0.806 |
Number of words in different subtests of the auditory verbal learning test expressed as mean ± SD (raw data). BL, baseline; FU, follow-up.
Paired t-test.
Wilcoxon signed-rank test.
ANOVARM, unadjusted.
ANCOVARM, adjusted for age, sex, APOE e4 status and education.